HUTCHMED (NASDAQ:HCM) Reaches New 1-Year Low – Here’s What Happened

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $11.70 and last traded at $11.70, with a volume of 13606 shares traded. The stock had previously closed at $11.99.

Analysts Set New Price Targets

A number of equities analysts have recently commented on HCM shares. Bank of America reduced their target price on shares of HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, March 10th. Morgan Stanley set a $13.60 price objective on shares of HUTCHMED in a research note on Thursday. Weiss Ratings lowered shares of HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 1st. Finally, Wall Street Zen lowered shares of HUTCHMED from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $16.80.

HUTCHMED Stock Performance

The company has a current ratio of 4.96, a quick ratio of 4.83 and a debt-to-equity ratio of 0.05. The company’s fifty day moving average price is $13.81 and its 200-day moving average price is $14.21.

HUTCHMED (NASDAQ:HCM) last posted its quarterly earnings data on Friday, March 6th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.50 by ($2.49). The firm had revenue of $135.42 million for the quarter, compared to analysts’ expectations of $290.50 million. On average, analysts anticipate that HUTCHMED will post 0.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On HUTCHMED

Hedge funds have recently added to or reduced their stakes in the business. Blue Trust Inc. grew its stake in shares of HUTCHMED by 131.5% during the 4th quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock worth $103,000 after purchasing an additional 4,378 shares during the period. Ameriprise Financial Inc. boosted its stake in shares of HUTCHMED by 4.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after acquiring an additional 698 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its stake in shares of HUTCHMED by 12.1% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,363 shares of the company’s stock worth $273,000 after acquiring an additional 1,873 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of HUTCHMED by 17.3% during the 2nd quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock worth $310,000 after acquiring an additional 3,035 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of HUTCHMED by 34.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock worth $342,000 after acquiring an additional 5,538 shares in the last quarter. 8.82% of the stock is owned by hedge funds and other institutional investors.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.